SCHEMBL5758928

SCHEMBL5758928

Cc1ccc(C(=O)NNc2ccc(F)cc2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.57
NPY5R Q15761 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.48
NOTUM Q6P988 1/20 0.47
MAPT P10636 3/20 0.43
ALDH1A1 P00352 3/20 0.43
GAA P10253 2/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
CCR1 P32246 1/20 0.41
THRB P10828 1/20 0.40
LMNA P02545 1/20 0.40
MET P08581 1/20 0.40
AXL P30530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756997 0.93 ELANE (0.58) ELANENPY5RSMN1; SMN2NOTUMMAPT
SCHEMBL5757787 0.92 ELANE (0.59) ELANENPY5RSMN1; SMN2NOTUMMAPT
SCHEMBL5759333 0.91 ELANE (0.56) ELANENPY5RSMN1; SMN2NOTUMMAPT
SCHEMBL5759697 0.91 ELANE (0.56) ELANENPY5RSMN1; SMN2NOTUMMAPT
SCHEMBL5758842 0.88 ELANE (0.74) ELANESMN1; SMN2NOTUMMAPTALDH1A1
SCHEMBL5757645 0.88 ELANE (0.54) ELANESMN1; SMN2NOTUMMAPTALDH1A1
SCHEMBL5757209 0.84 ELANE (0.79) ELANENPY5RSMN1; SMN2NOTUMMAPT
SCHEMBL5757915 0.82 ELANE (0.65) ELANENPY5RSMN1; SMN2NOTUMALDH1A1
SCHEMBL5759890 0.81 ELANE (0.64) ELANENPY5RNOTUMCCR1DDR1
SCHEMBL5754791 0.80 ELANE (0.58) ELANENPY5RSMN1; SMN2NOTUMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885NPY5R 597/4885SMN1; SMN2 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.